Group 1 - The innovative drug sector is experiencing a significant rise, with companies such as Shutaishen (300204), Rejing Bio, Kangchen Pharmaceutical (603590), Fuyuan Pharmaceutical (601089), and Yuekang Pharmaceutical reaching historical highs during trading [1] - Qizheng Tibetan Medicine (002287) has achieved three consecutive trading limit increases, while Hanshang Group (600774) has seen two consecutive limit increases [1] - Other companies including Lianhuan Pharmaceutical (600513), Guizhou Bailing (002424), Anglikang (002940), Xintian Pharmaceutical (002873), and Zhongsheng Pharmaceutical (002317) have also hit trading limits, with Weikang Pharmaceutical (300878) and Dajia Weikang (301126) rising over 10% [1]

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the drug registration certificate for the combination drug Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, which is expected to enhance the company's product pipeline [1][2]. Group 1: Drug Information - The Sitagliptin Metformin Extended-Release Tablets are a compound formulation intended for adult patients with type 2 diabetes who are currently receiving treatment with Sitagliptin and Metformin Extended-Release Tablets [1]. - The company received the acceptance notice for the drug's marketing authorization application in January 2024 and has recently obtained the drug registration certificate, which is considered equivalent to passing the consistency evaluation according to national policies [1]. Group 2: Impact on the Company - The approval of Sitagliptin Metformin Extended-Release Tablets will further enrich the company's product pipeline [2]. - Due to the unique nature of the pharmaceutical industry, drug sales may be significantly affected by national policies and market environment changes, leading to considerable uncertainty in specific sales outcomes [2].

Group 1 - The core point of the article is that Anglikon has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [2] Group 2 - The announcement was made on the evening of July 31 [2] - The drug registration certificate is a significant regulatory milestone for the company [2] - This development may enhance the company's product portfolio in the diabetes treatment market [2]

Group 1 - Jiejia Weichuang expects a net profit of 1.7 billion to 1.96 billion yuan for the first half of 2025, representing a year-on-year increase of 38.65% to 59.85% [1] - Micron Biotech's CS231295 clinical trial application has been approved by the FDA for treating advanced solid tumors [1] - Sinopec anticipates a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, a decrease of 39.5% to 43.7% year-on-year [2] Group 2 - High Energy Environment has obtained a loan commitment letter from a financial institution for share repurchase [2] - Electric Power Investment Energy received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inadequate disclosure in its semi-annual report [3] - Zhejiang University Net New won a bid for an intelligent engineering project worth 94.2712 million yuan [5] Group 3 - Daodaoquan reported a net profit of 181 million yuan for the first half of 2025, a year-on-year increase of 563.15% [8] - New Light Optoelectronics expects a net loss of 19 million to 23 million yuan for the first half of 2025 [9] - Aihua Pharmaceutical's two probiotic powder registration applications have been accepted [10] Group 4 - Xinhui Electric's subsidiary signed a product sales framework contract for commercial and household robots [11] - Baida Precision Engineering's subsidiary obtained 134,500 square meters of industrial land use rights [12] - Haiyang Technology's chief engineer resigned for personal reasons [13] Group 5 - Tianhe Magnetic Materials received a project filing notice for a 12,000-ton magnetic material deep processing project [22] - Wanlima is the pre-selected unit for a procurement project worth 43.835 million yuan from China Southern Airlines [24] - Yipin Hong's subsidiaries obtained two drug registration certificates [25] Group 6 - Zhejiang Jiaoke's subsidiary signed new construction projects worth 4.783 billion yuan in the second quarter [27] - Shenglan Co. received approval for issuing convertible bonds [29] - Jimi Technology expects a net profit of 88.6622 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [31] Group 7 - Dingtong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06% [32] - Huaheng Biological is planning to list on the Hong Kong Stock Exchange [34] - Yuntian Lihui submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [36] Group 8 - Nanchip Technology expects a net profit of 108.8 million to 133.1 million yuan for the first half of 2025, a decrease of 35.09% to 47.03% year-on-year [43] - Anglikang's Mesobam injection has received a drug registration certificate [44] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.998% [45]

近半年该股累计上榜龙虎榜10次，上榜次日股价平均涨1.76%，上榜后5日平均涨2.58%。 资金流向方面，今日该股主力资金净流入1.87亿元，其中，特大单净流入1.63亿元，大单资金净流入 2425.75万元。近5日主力资金净流入879.32万元。（数据宝） 昂利康今日涨停，全天换手率11.32%，成交额11.65亿元，振幅8.87%。龙虎榜数据显示，机构净买入 1.72亿元，营业部席位合计净卖出2060.64万元。 深交所公开信息显示，当日该股因日涨幅偏离值达11.39%上榜，机构专用席位净买入1.72亿元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.07亿元，其中，买入成交额为2.29亿 元，卖出成交额为7742.32万元，合计净买入1.52亿元。 具体来看，今日上榜的营业部中，共有6家机构专用席位现身，即买一、买二、买三、买四、买五、卖 一、卖五，合计买入金额2.05亿元，卖出金额3235.10万元，合计净买入1.72亿元。 昂利康7月31日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | ...

7月31日，昂利康公告，公司获得国家药品监督管理局核准签发的西格列汀二甲双胍缓释片《药品注册 证书》。西格列汀二甲双胍缓释片为复方制剂，适用于正在接受西格列汀和二甲双胍缓释片联合治疗的 成人2型糖尿病患者。公司于2024年1月获得西格列汀二甲双胍缓释片药品上市许可申请受理通知书，并 于近日获得国家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》视同通过一致性评 价。 ...

Group 1 - The company, Anglikang (002940.SZ), has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [1] - Sitagliptin Metformin Extended-Release Tablets are a compound preparation suitable for adult patients with type 2 diabetes who are currently receiving combined treatment with Sitagliptin and Metformin Extended-Release Tablets [1]

| 买入金额最大的前5名 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 交易营业部名称 | | | 买入金额(万) | 占总成交比例 | 卖出金额(万) | 占总成交比例 | 净额(万)® | | 1 | 机构专用 | 1414次 43.42% | 0 | 8269.79 | 7.10% | 0.00 | 0.00% | 8269 79 | | 2 | 机构专用 | 1414次 43 42% | ▶ | 3797.68 | 3.26% | 126.59 | 0.11% | 3671.09 | | 3 | 机构专用 | 1414次 43.42% | A | 3490.92 | 3.00% | 1960.58 | 1.68% | 1530.34 | | 4 | 机构专用 | 1414次 43.42% | | 2990.94 | 2.57% | 0.00 | 0.00% | 2990.94 | | 5 | 机构专用 | 1414次 43.42% | ▶ | 1913.61 | 1.64% | 0.00 ...

（文章来源：智通财经） 昂利康今日涨停，成交额11.65亿元，换手率11.32%，盘后龙虎榜数据显示，5家机构专用席位净买入 1.84亿元，有1家机构专用席位净卖出1147.94万元。 ...

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its product, Sitagliptin Metformin Extended-Release Tablets, indicating a significant regulatory milestone for the company in the diabetes treatment market [1] Group 1 - The Sitagliptin Metformin Extended-Release Tablets are a compound formulation designed for adult patients with type 2 diabetes who are currently undergoing treatment with both Sitagliptin and Metformin Extended-Release Tablets [1]